Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc announced preliminary top-line results from a phase II clinical trial of cariprazine (RGH-188), an investigational antipsychotic, in patients with acute mania associated with bipolar I disorder.
convey_url = “http%3A%2F%2Fmed-term.com%2F2008%2F10%2F02%2Fforest-laboratories-inc-and-gedeon-richter-plc-announce-positive-phase-ii-results-with-the-investigational-antipsychotic-cariprazine%2F”;convey_source = “English”;convey_user = “wordpress”;convey_type = 1;









